Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by NewAmsterdam Pharma Company B.V.
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
August 14, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
August 07, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease
July 25, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares
June 09, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares
June 06, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares
June 06, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients
June 05, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
June 03, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma to Present at Jefferies Healthcare Conference
May 31, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
May 23, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights
May 08, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
April 24, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
April 03, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
March 31, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma to Present at Cowen 43rd Annual Health Care Conference
March 01, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference
February 09, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors
February 06, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
January 17, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Announces Appointment of David Topper as Chief Financial Officer
December 19, 2022
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
NAMS
NAMSW
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease
November 23, 2022
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
Tickers
FLAC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.